FY2018 EPS Estimates for Ultragenyx Pharmaceutical Raised by SunTrust Banks (RARE)

Ultragenyx Pharmaceutical (NASDAQ:RARE) – SunTrust Banks boosted their FY2018 earnings estimates for shares of Ultragenyx Pharmaceutical in a report issued on Wednesday, April 18th. SunTrust Banks analyst E. Nash now expects that the biopharmaceutical company will post earnings per share of ($6.59) for the year, up from their previous estimate of ($6.63). SunTrust Banks has a “Buy” rating and a $55.00 price objective on the stock. SunTrust Banks also issued estimates for Ultragenyx Pharmaceutical’s Q4 2018 earnings at ($1.63) EPS, FY2019 earnings at ($5.53) EPS, FY2020 earnings at ($5.28) EPS, FY2021 earnings at $0.23 EPS and FY2022 earnings at $5.70 EPS.

How to Become a New Pot Stock Millionaire

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported ($2.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.00) by ($0.27). The business had revenue of $2.41 million for the quarter, compared to the consensus estimate of $0.75 million. During the same quarter in the previous year, the business earned ($1.75) earnings per share.

Several other analysts also recently issued reports on the stock. Cowen reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday. Stifel Nicolaus upped their price target on shares of Ultragenyx Pharmaceutical from $74.00 to $77.00 and gave the company a “buy” rating in a report on Wednesday. Wedbush reaffirmed a “positive” rating and issued a $71.00 price target (up previously from $64.00) on shares of Ultragenyx Pharmaceutical in a report on Wednesday. JMP Securities upped their price target on shares of Ultragenyx Pharmaceutical from $70.00 to $74.00 and gave the company an “outperform” rating in a report on Wednesday. Finally, Bank of America upped their price target on shares of Ultragenyx Pharmaceutical from $61.00 to $72.00 in a report on Tuesday. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $69.76.

Shares of NASDAQ RARE opened at $53.87 on Friday. Ultragenyx Pharmaceutical has a 12-month low of $41.67 and a 12-month high of $71.99. The stock has a market capitalization of $2,723.86, a price-to-earnings ratio of -7.18 and a beta of 1.83.

Institutional investors and hedge funds have recently made changes to their positions in the stock. California Public Employees Retirement System raised its stake in Ultragenyx Pharmaceutical by 3.1% during the third quarter. California Public Employees Retirement System now owns 40,300 shares of the biopharmaceutical company’s stock worth $2,146,000 after purchasing an additional 1,200 shares during the period. UBS Asset Management Americas Inc. raised its stake in Ultragenyx Pharmaceutical by 6.5% during the fourth quarter. UBS Asset Management Americas Inc. now owns 26,662 shares of the biopharmaceutical company’s stock worth $1,237,000 after purchasing an additional 1,636 shares during the period. Jane Street Group LLC raised its stake in Ultragenyx Pharmaceutical by 26.1% during the fourth quarter. Jane Street Group LLC now owns 8,821 shares of the biopharmaceutical company’s stock worth $409,000 after purchasing an additional 1,828 shares during the period. Cornerstone Capital Management Holdings LLC. raised its stake in Ultragenyx Pharmaceutical by 11.7% during the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 19,098 shares of the biopharmaceutical company’s stock worth $885,000 after purchasing an additional 2,000 shares during the period. Finally, Swiss National Bank raised its stake in Ultragenyx Pharmaceutical by 4.0% during the fourth quarter. Swiss National Bank now owns 69,952 shares of the biopharmaceutical company’s stock worth $3,244,000 after purchasing an additional 2,700 shares during the period. 87.19% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “FY2018 EPS Estimates for Ultragenyx Pharmaceutical Raised by SunTrust Banks (RARE)” was published by Week Herald and is the sole property of of Week Herald. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://weekherald.com/2018/04/20/fy2018-eps-estimates-for-ultragenyx-pharmaceutical-raised-by-suntrust-banks-rare.html.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply